Join Clinical Trials in Michigan for Cancer

All Categories Most Often Searched » Cancer » Michigan

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Condition: Breast Cancer
Intervention: Drug: enzalutamide
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention:
Sponsors: Fujirebio Diagnostics, Inc.; Fujirebio Diagnostics, Inc.; Medical Research Networx LLC
Recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
A Clinical Study Testing The Safety and Efficacy of CH5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer

Condition: ALK-Rearranged Non-Small Cell Lung Cancer
Interventions: Drug: CH5424802; Drug: CH5424802; Drug: CH5424802
Sponsors: Chugai Pharmaceutical; Chugai Pharmaceutical
Recruiting - verified May 2012
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

Condition: Oral Squamous Cell Cancer
Intervention: Other: saliva collection prior to clinically driven biopsy of oral lesion
Sponsors: PeriRx; PeriRx
Recruiting - verified April 2012
Saw Palmetto: Symptom Management for Men During Radiation Therapy

Condition: Prostate Cancer
Intervention: Drug: Saw Palmetto
Sponsors: Michigan State University; Michigan State University
Recruiting - verified April 2012
A Pilot Study To Assess Guidance in and Subsequent Use of Mind-Body Techniques on the Quality of Life of Cancer Patients

Conditions: Quality of Life; Life Change Events; Neoplasms
Interventions: Behavioral: Face-to-Face MBM Skills Group; Other: Waitlist Control I; Other: Waitlist Control II; Behavioral: Online MBM Skills Group
Sponsors: Absenger Cancer Education Foundation; Absenger Cancer Education Foundation
Not yet recruiting - verified April 2012
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012
The Ultrasound Study of Tamoxifen

Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients

Condition: Breast Cancer
Intervention: Other: Reflexology
Sponsors: Michigan State University; Michigan State University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii Cancer Research Center; University of Vermont
Not yet recruiting - verified April 2012
Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Condition: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Intervention: Drug: Metformin
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified March 2012
A Study of Ramucirumab and Docetaxel in Patients With Solid Tumors

Condition: Malignant Solid Tumor
Interventions: Biological: Ramucirumab; Drug: Docetaxel
Sponsors: ImClone LLC; ImClone LLC
Not yet recruiting - verified March 2012
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Condition: Lymphoma, Solid Tumour
Interventions: Drug: GDC-0575; Drug: gemcitabine
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Mindfulness Therapy for Individuals With Lung Cancer

Condition: Lung Cancer
Interventions: Behavioral: symptom assessment; Behavioral: Mindfulness Intervention
Sponsors: Michigan State University; Michigan State University
Not yet recruiting - verified March 2012
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Neoplasms
Interventions: Drug: GDC-0973; Drug: GDC-0068
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2012
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Condition: Solid Cancers
Intervention: Drug: Vismodegib
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012
Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery

Conditions: Colon Cancer; Rectal Cancer; Colonic Diverticulosis
Interventions: Device: Continuous Preperitoneal Analgesia; Device: Continuous Epidural Analgesia
Sponsors: Saint Joseph Mercy Health System; Saint Joseph Mercy Health System
Recruiting - verified March 2012
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Conditions: Hepatitis C; Hepatocellular Carcinoma
Intervention: Drug: GS-7977+RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: tacrolimus; Biological: rituximab; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Other: pharmacological study; Drug: tacrolimus; Drug: sirolimus; Biological: anti-thymocyte globulin; Drug: fludarabine phosphate; Drug: busulfan; Drug: bortezomib; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Condition: Actinic Keratosis
Interventions: Procedure: Cryotherapy; Drug: Vehicle; Drug: Ingenol metabute
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2012
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: TAS266
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)

Condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Intervention: Drug: CO-1686
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified March 2012
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Condition: Locally Advanced HER2-Negative Breast Cancer
Interventions: Drug: Eribulin Mesylate; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Not yet recruiting - verified March 2012
A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors

Condition: Malignant Solid Tumor
Interventions: Biological: ramucirumab (IMC-1121B); Drug: paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Not yet recruiting - verified May 2012
Decision Aid to Technologically Enhance Shared Decision Making

Condition: Colorectal Cancer
Intervention: Behavioral: Colorectal Web
Sponsors: University of Michigan Health System; University of Michigan Health System
Not yet recruiting - verified March 2012
Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Interventions: Drug: oral azacitidine; Drug: oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

Condition: Lymphoma
Interventions: Drug: Lamivudine; Drug: Tenofovir disoproxil fumarate
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified February 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: TPI 287; Drug: Temozolomide; Drug: Irinotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Archer Biosciences, Inc.
Recruiting - verified April 2012
Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Behavioral: telephone-based intervention; Drug: mercaptopurine; Other: computer-assisted intervention; Other: counseling intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Conditions: Gastrointestinal Cancer; Nausea Post Chemotherapy
Intervention: Drug: fosaprepitant dimeglumine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Condition: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Intervention: Drug: GRN1005
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified April 2012
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Conditions: Cancer Survivor; Human Papilloma Virus Infection
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: questionnaire administration; Other: laboratory biomarker analysis; Other: survey administration; Other: medical chart review
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Compare Propofol to Fentanyl and Midazolam for Colonoscopy

Conditions: Colon Cancer; Rectal Cancer; Colonic Diverticulosis
Interventions: Drug: Fentanyl; Drug: Propofol; Drug: Midazolam
Sponsors: Saint Joseph Mercy Health System; Saint Joseph Mercy Health System
Recruiting - verified December 2011
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012
Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: Oral azacitidine plus Abraxane; Drug: Carboplatin; Drug: Abraxane
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Intervention: Drug: TPI 287
Sponsors: Van Andel Research Institute; Giselle Sholler; Van Andel Research Institute; Archer Biosciences, Inc.
Recruiting - verified April 2012
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib; Drug: Pralatrexate; Drug: Romidepsin; Drug: Gemcitabine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified January 2012
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: docetaxel; Drug: pasireotide; Drug: prednisone
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Drug: alisertib; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Defined Green Tea Catechin Extract in Treating Patients With Plasma Cell Neoplasm Or Smoldering Multiple Myeloma

Conditions: Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma
Interventions: Dietary Supplement: defined green tea catechin extract; Biological: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Axitinib (AG-013736)
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified January 2012
Adverse Event Toxicity Intervention Study To Evaluate The Effect Of Prophylactic Treatment And An Interrupted Dosing Schedule On The Incidence Of Adverse Events In Patients Treated With Dacomitinib (PF-00299804)

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012
Study of ABT-700 in Subjects With Advanced Solid Tumors

Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Eribulin; Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen

Condition: Acute Myeloblastic Leukemia
Interventions: Drug: Clofarabine/Busulfan x 4; Procedure: Peripheral blood stem cell transplant
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Genzyme; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified November 2011
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

Condition: HIV Infection
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: LGH447
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide; Drug: pazopanib hydrochloride
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified November 2011
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

Conditions: Liver Cancer; Hepatocellular Cancer
Intervention: Radiation: individualized Stereotactic Body Radiation Therapy (SBRT)
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified January 2012
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)

Condition: Hepatocellular Carcinoma
Intervention: Radiation: Liver Irradiation
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified January 2012
MSC2015103B in Solid Tumors

Condition: Advanced Solid Tumor
Interventions: Drug: MSC2015103B; Drug: MSC2015103B
Sponsors: EMD Serono; EMD Serono
Recruiting - verified March 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: APC-100
Sponsors: Adamis Pharmaceuticals Corporation; Adamis Pharmaceuticals Corporation
Recruiting - verified September 2011
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
Sponsors: University of Michigan Cancer Center; David C Smith; Exelixis
Recruiting - verified March 2012
Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Conditions: Uterine Fibroids; Heavy Uterine Bleeding
Interventions: Drug: placebo; Drug: elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo Cohort 4; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified April 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS); Duke University; Children's Hospital of Michigan; Baylor College of Medicine; Texas Children's Hospital; Wills Eye; Nationwide Children's Hospital
Recruiting - verified February 2012
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Conditions: Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer
Interventions: Drug: FOLFOX6; Biological: EGFRBi armed ATC Infusions
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified September 2011
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Dose Escalation Study of INK1117 in Subjects With Advanced Cancer

Condition: Metastatic Solid Tumors
Intervention: Drug: INK1117
Sponsors: Intellikine; Intellikine
Recruiting - verified February 2012
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: decitabine
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: tacrolimus; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Conditions: Tumors; Medical Oncology; Neoplasms
Intervention: Drug: AGS-22M6E
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.; Seattle Genetics, Inc.
Recruiting - verified March 2012
Association Between Hepatitis C Infection and Renal Cell Carcinoma

Conditions: Hepatitis C; Renal Cell Carcinoma; Colorectal Cancer
Intervention: Other: Hepatitis C testing
Sponsors: Henry Ford Health System; Henry Ford Health System; Schering-Plough
Recruiting - verified June 2011
Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220; Drug: Cytarabine; Drug: Etoposide; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Ambit Biosciences Corporation
Recruiting - verified September 2011
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Biological: Sym004
Sponsors: Symphogen A/S; Symphogen A/S
Recruiting - verified February 2012
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Lymphoma; Neurotoxicity; Radiation Toxicity
Interventions: Biological: rituximab; Drug: cytarabine; Drug: methotrexate; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Biospecimens for Identification of Diseases of the Pancreas.

Conditions: Pancreatic Cancer; Chronic Pancreatitis; Type II Diabetes; Pancreatic Cysts; Control
Intervention: Procedure: Blood Draw
Sponsors: University of Michigan; University of Michigan
Recruiting - verified January 2012
Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

Conditions: Barrett Esophagus; Esophageal Adenocarcinoma
Intervention: Drug: GI heptapeptide
Sponsors: University of Michigan; University of Michigan
Recruiting - verified January 2012
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: placebo
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: Low dose methotrexate and Bexxar
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline
Recruiting - verified August 2011
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: linifanib
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: stereotactic radiosurgery; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Conditions: Solid Tumor; Colorectal Cancer; Endometrial Cancer
Intervention: Drug: DS-7423
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Conditions: Advanced Solid Tumors,; Selected Solid Tumors
Intervention: Drug: BKM120 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Condition: Solid Tumour
Interventions: Drug: GDC-0425; Drug: gemcitabine
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Conditions: Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
Interventions: Drug: E7050; Drug: cisplatin; Drug: capecitabine
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: BMS-833923
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Condition: Cancer
Interventions: Drug: AMP-224; Drug: AMP-224
Sponsors: Amplimmune; Amplimmune; GlaxoSmithKline
Recruiting - verified May 2012
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Intervention: Device: Guided Therapy
Sponsors: Van Andel Research Institute; Giselle Sholler
Recruiting - verified April 2012
A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF)

Condition: Cancer Survivor
Interventions: Drug: carvedilol; Other: placebo; Other: pharmacogenomic studies; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Inotuzumab Ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Condition: Colon Cancer and Rectal Cancer
Interventions: Drug: FOLFIRI; Drug: E7820
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Condition: Solid Tumors
Intervention: Biological: OMP-18R5
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified December 2011
MaxAn Post Market Surveillance Validation

Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Conditions: Drug Interactions; BRAF; Cancer
Interventions: Drug: Warfarin; Drug: Ketoconazole; Drug: Gemfibrozil; Drug: GSK2118436 150mg; Drug: GSK2118436 75mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Conditions: Pain; Pancreatic Cancer
Intervention: Procedure: Cryoablation using Galil Medical systems and needles
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Conditions: Extra-adrenal Paraganglioma; Paraganglioma; Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood; Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Panobinostat
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Novartis
Recruiting - verified November 2011
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Effectiveness of Open and Robotic Prostatectomy

Condition: Prostate Cancer
Intervention: Other: Questionnaire
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; The Cleveland Clinic; Johns Hopkins University; University of California, San Francisco; University of Michigan; Vanderbilt University; Washington University School of Medicine
Recruiting - verified May 2012
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors

Condition: Solid Tumors
Interventions: Drug: CEP-9722; Drug: CEP-9722
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

Condition: Metastatic Lung Cancer
Intervention: Device: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Drug: MM-302
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified November 2011
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Biosciences; BIND Biosciences
Recruiting - verified June 2011
Monitor Response to Treatment in Neuroblastoma Using 3'-Deoxy-3'-Fluorothymidine- Positron Emission Tomography (FLT-PET)

Condition: Neuroblastoma
Intervention: Device: FLT-PET
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Sapacitabine and decitabine; Drug: Decitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified March 2012
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified April 2012
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors; Advanced Ovarian Cancer
Intervention: Drug: U3-1565
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012
GSK1120212 Rollover Study

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Docetaxel + GSK1120212; Drug: Erlotinib + GSK1120212; Drug: Pemetrexed + GSK1120212; Drug: Carboplatin + GSK1120212; Drug: Nab-paclitaxel + GSK1120212; Drug: Gemcitabine + GSK1120212; Drug: Everolimus + GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
A Study of DS-2248, in Subjects With Advanced Solid Tumors

Conditions: Solid Tumors; Non-small Cell Lung Carcinoma
Intervention: Drug: DS-2248
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Daiichi Sankyo Development Ltd
Recruiting - verified March 2012
A Study of LY2875358 in Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: LY2875358; Drug: LY2875358 + erlotinib; Drug: LY2875358 at MTD
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Intervention: Drug: BMS-906024
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Conditions: Advanced Malignancies; B-Cell Lymphoma; Solid Tumor
Intervention: Drug: ASP3026
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified February 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: DSTP3086S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Lapatinib Ditosylate and MK2206 in Treating Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: lapatinib ditosylate; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: AT-101; Drug: Docetaxel
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified October 2011
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

Condition: Solid Tumors
Intervention: Drug: OMP-59R5
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified December 2011
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: Hsp90 inhibitor STA-9090; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Genetic: RNA analysis; Other: spectrophotometry; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: gene expression analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Condition: Solid Organ Tumors
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: HCD122
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: Sorafenib
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified May 2012
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel

Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

Condition: Acute Myelogenous Leukemia (AML)
Intervention: Drug: AT-406 in combination with daunorubicin and cytarabine
Sponsors: Ascenta Therapeutics; Ascenta Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified January 2012
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2011
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study of AMG 337 in Subjects With Advanced Solid Tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 337
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor

Condition: Advanced Solid Tumors
Interventions: Drug: MEDI3617; Drug: MEDI3617 - Dose Expansion (CRC); Drug: MEDI3617 - Dose Expansion (NSCLC); Drug: MEDI3617 Single-Agent Optional Dose Expansion; Drug: MEDI3617 + Bev Q3W Dose Escalation; Drug: MEDI3617 + Bev Q2W Dose Escalation; Drug: MEDI3617 + Bev Optional Dose Expansion; Drug: MEDI3617 + Weekly Pax Dose Escalation; Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc; Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Condition: Hematological Malignancies
Intervention: Drug: Tacrolimus and Thymoglobulin
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified March 2012
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus; Drug: cyclophosphamide; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

Conditions: Stomach Cancer; Esophageal Cancer
Interventions: Biological: Ramucirumab; Drug: Placebo; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Conditions: Advanced Solid Tumor; Lymphomas
Intervention: Drug: LEE011
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Entinostat and Anastrozole or Tamoxifen in Treating Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Capecitabine
Sponsors: Adherex Technologies, Inc.; Adherex Technologies, Inc.
Recruiting - verified August 2011
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Conditions: Myelodysplastic Syndromes; MDS; RAEB; Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: multitargeted tyrosine kinase inhibitor BIBF 1120
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, B-cell; Lymphoma, B-cell, Diffuse
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Conditions: Non Small Cell Lung Cancer; NSCLC
Interventions: Drug: OSI-906; Drug: Erlotinib; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Condition: Sarcoma
Interventions: Drug: ixabepilone; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: Drug: U3-1287; Drug: Erlotinib
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Dasatinib Combo With SMO Inhibitor (BMS-833923)

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: BMS-833923
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: zoledronate therapy
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; Department of Defense
Recruiting - verified November 2011
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: isotretinoin; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Interventions: Drug: DCDT2980S; Drug: rituximab
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib (Nexavar, Bay43-9006); Drug: Sorafenib (Nexavar, Bay43-9006)
Sponsors: University of Florida; University of Florida
Recruiting - verified April 2012
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

Condition: Pancreatic Cancer
Interventions: Drug: GDC-0449; Drug: Gemcitabine
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012
Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Interventions: Drug: TL32711; Drug: TL32711
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Recruiting - verified November 2011
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Biological: ofatumumab
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Condition: Head and Neck Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified September 2011
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Condition: Solid Tumor
Intervention: Drug: PEGPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2011
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Rituximab; Drug: Etoposide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2010
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Condition: Chordoma
Intervention: Drug: Imatinib + LBH589
Sponsors: University of Virginia; Deric M Park MD
Recruiting - verified February 2012
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified November 2011
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Laboratory-Treated T Cells After Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
HOME Study: Hysteroscopic Office Myomectomy Evaluation

Conditions: Uterine Fibroids; Polyps
Intervention: Device: Hysteroscopic Morcellator (The MyoSure Tissue Removal Device)
Sponsors: Hologic, Inc.; Hologic, Inc.
Recruiting - verified October 2011
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Condition: Sarcoma
Interventions: Biological: Trivalent ganglioside vaccine; Biological: OPT-821
Sponsors: MabVax Therapeutics, Inc.; MabVax Therapeutics, Inc.
Recruiting - verified March 2012
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Validation of a Multi-gene Test for Lung Cancer Risk

Condition: Lung Cancer
Intervention: Genetic: Lung Cancer Risk Test
Sponsors: University of Toledo Health Science Campus; University of Toledo Health Science Campus; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Conditions: Stage IIIC Melanoma; Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230); Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012
A Study of IMC-RON8 in Advanced Solid Tumors

Condition: Cancer
Interventions: Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified November 2011
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: management of therapy complications; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Study to Assess Safety, Tolerability and PK of AZD1480 Alone or in Comb With Docetaxel in Patients With Solid Tumours

Condition: Solid Malignancies
Intervention: Drug: AZD1480
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Conditions: Glioblastoma; GBM; Glioblastoma Multiforme
Intervention: Drug: PF-00299804
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Henry Ford Hospital; Pfizer
Recruiting - verified April 2012
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

Condition: Endometrial Cancer
Intervention: Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Conditions: Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions: Drug: Pazopanib (GW786034); Drug: Paclitaxel
Sponsors: Stanford University; Sandy Srinivas; GlaxoSmithKline
Recruiting - verified April 2012
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Condition: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: Duke University; Duke University; Novartis; Pfizer
Recruiting - verified February 2012
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified December 2011
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011
Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Contrast-Enhanced CT Scan and Contrast-Enhanced MRI in Diagnosing and Staging Liver Cancer in Patients With Chronic Liver Disease

Condition: Liver Cancer
Interventions: Drug: iodinated contrast dye; Drug: motexafin gadolinium; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy

Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2012
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Conditions: Cancer; Solid Tumors; Lymphoma; Malignancy
Intervention: Drug: AT-406
Sponsors: Ascenta Therapeutics; Ascenta Therapeutics
Recruiting - verified January 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Condition: Chronic Lymphocytic Leukemia
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2011
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
A Dose-escalation Study in Subjects With Advanced Malignancies

Condition: Advanced Malignancies
Intervention: Drug: INCB028060
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified April 2012
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Condition: Prostate Cancer
Interventions: Drug: carboplatin; Drug: everolimus; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Aspirin in Reducing Events in the Elderly

Conditions: Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding
Interventions: Drug: 100 mg enteric-coated aspirin; Drug: Placebo
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation; National Health and Medical Research Council, Australia; Bayer; Monash University; Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Amrubicin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified July 2011
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: No Intervention
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified March 2012
A Study for Patients With Small-Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Drug: LY2523355
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Condition: Lymphoma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Rituximab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Cephalon
Recruiting - verified July 2011
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

Conditions: Endometrial Cancer; Endometrial Neoplasms
Intervention: Drug: XL147 (SAR245408)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: fluorescence in situ hybridization; Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of Tissue and Blood Samples From Patients With High-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Conditions: Advanced Solid Tumors With FGFR1 Amplication,; Advanced Solid Tumors With FGFR2 Amplication,; Advanced Solid Tumors With FGFR3 Mutation
Intervention: Drug: BGJ398
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Solid Cancers
Interventions: Drug: GDC-0941; Drug: GDC-0973/XL518
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Conditions: ErbB2 Overexpressing; Solid Tumors; Metastatic Breast Cancer; Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012
Care Partners: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy

Condition: Cancer
Intervention: Behavioral: Caregiver website
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Michigan State University; University of Michigan; VA Puget Sound Health Care System; Fargo VA Medical Center
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Condition: Advanced Malignancies, Non-small Cell Lung Cancer
Interventions: Drug: MGCD265+erlotinib; Drug: MGCD265+docetaxel
Sponsors: MethylGene Inc.; MethylGene Inc.
Recruiting - verified November 2011
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified November 2011
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Condition: Advanced Malignancies
Intervention: Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified November 2011
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Conditions: Advanced Non-hematologic Malignancies; Advanced Metastatic Melanoma
Intervention: Drug: TAK-733
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

Condition: Solid Tumors
Interventions: Drug: Genz-644282 (28-day dosing schedule); Drug: Genz-644282 (21-day dosing schedule)
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2012
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Dietary Supplement: defined green tea catechin extract; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Conditions: Renal Cell Carcinoma; Non-hodgkin's Lymphoma
Intervention: Biological: MDX-1203
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Condition: Cancer
Intervention: Drug: PF-04691502
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Condition: Solid Cancer
Intervention: Drug: cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: pulmonary function testing
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Lymphoseek
Sponsors: Navidea Biopharmaceuticals; Navidea Biopharmaceuticals
Recruiting - verified March 2012
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: MLN4924; Drug: MLN4924 and azacitidine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

Condition: Pulmonary Nodule
Interventions: Drug: dexamethasone; Procedure: computed tomography; Radiation: fludeoxyglucose F 18
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: cone biopsy; Procedure: endocervical curettage; Procedure: histopathologic examination; Procedure: loop electrosurgical excision procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis

Conditions: Lung Cancer; Metastatic Cancer
Interventions: Procedure: central lymph node dissection; Procedure: computed tomography; Procedure: cryosurgery; Procedure: positron emission tomography; Procedure: regional lymph node dissection; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2011
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: oral microencapsulated diindolylmethane; Other: high performance liquid chromatography; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: mass spectrometry; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Conditions: Prostate Cancer; Prostatic Neoplasms
Interventions: Drug: Panobinostat (Phase II doses); Drug: Panobinostat
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis
Recruiting - verified March 2012
A Trial In Patients With Advanced Cancer And Leukemia

Conditions: Neoplasms by Histologic Type; Leukemia, Lymphoid; Leukemia, T-Cell; Solid Tumors
Intervention: Drug: PF-03084014
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Condition: Advanced Solid Malignancies
Interventions: Drug: REGN421; Drug: REGN421
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified October 2011
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Condition: Solid Cancers
Intervention: Drug: GDC-0941
Sponsors: Genentech; Genentech
Recruiting - verified September 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study

Condition: Breast Cancer
Intervention:
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound

Conditions: Breast Masses; Breast Cysts
Intervention: Procedure: Breast Ultrasound imaging
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified May 2012
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Radiation: CyberKnife Stereotactic Radiotherapy; Procedure: Surgery
Sponsors: Accuray Incorporated; Accuray Incorporated; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study for Patients With Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Conditions: Hematologic Malignancies; Graft vs Host Disease
Interventions: Procedure: reduced intensity, matched related donor stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: vorinostat
Sponsors: University of Michigan Cancer Center; Pavan Reddy, MD
Recruiting - verified February 2012
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab; Drug: 5-FU; Drug: oxaliplatin; Drug: leucovorin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Bristol-Myers Squibb
Recruiting - verified March 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Conditions: Locally Advanced (Unresectable) Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: gemcitabine; Drug: Erlotinib; Radiation: low dose fractionated radiotherapy
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified November 2011
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Prospective Study Differentiating Recurrent Brain Tumor Versus Radiation Injury Using Magnetic Resonance (MR) Spectroscopy, Diffusion Tensor Imaging and Diffusion Weighted Imaging on 3T MR Scanner

Conditions: Radiation Injury; Brain Tumor
Intervention:
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified June 2011
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified June 2011
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: Saracatinib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified March 2012
Digital Mammography: Computer-Aided Breast Cancer Diagnosis

Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: digital mammography
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Metastatic Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified October 2011
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)

Condition: Brain Tumors
Intervention: Procedure: MRI
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH); National Cancer Institute (NCI); The Dana Foundation
Recruiting - verified August 2011
Breast Lesion Analysis for Tomosynthesis Mammography

Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: Computer aided analysis of breast lesions
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified August 2011
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Condition: Any Solid Tumor or Lymphoma
Intervention: Drug: OSI-027
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme; National Cancer Institute (NCI)
Recruiting - verified May 2012
Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Condition: Solid Tumors
Intervention: Drug: STA 9090 (ganetespib)
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified July 2011
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Condition: Glioblastoma
Intervention: Drug: bsi-201 plus temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified June 2011
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Conditions: Breast Cancer; Depression; Hot Flashes; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: citalopram hydrobromide; Drug: escitalopram oxalate; Drug: gabapentin; Drug: sertraline hydrochloride; Drug: tamoxifen citrate; Drug: venlafaxine; Genetic: molecular genetic technique; Other: high performance liquid chromatography; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: pemetrexed disodium; Drug: docetaxel
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Conditions: Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Neoplasm Metastasis; Brain Neoplasms
Interventions: Drug: ABT-888; Radiation: Whole Brain Radiation Therapy
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma

Condition: Diffuse Large B Cell Lymphoma
Intervention: Procedure: diffusion MRI
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified July 2011
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: Irinotecan and Bortezomib
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified July 2011
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

Condition: Breast Cancer
Interventions: Procedure: Alloderm, Questionnaires; Procedure: Without ALLODERM, Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Michigan; University of North Carolina, Chapel Hill
Recruiting - verified December 2011
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
Pazopanib in Treating Patients With Advanced Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2011
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Liver Cancer; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

Condition: Dysphagia
Intervention: Device: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Sponsors: Boston Medical Center; Boston Medical Center; Northwestern University; Boston University; University of Wisconsin, Madison; New York University; VA Boston Healthcare System; Lahey Clinic; Lenox Hill Hospital; Beth Israel Medical Center; Greater Baltimore Medical Center; Medical College of Wisconsin; Community Medical Center, Inc; Henry Ford Hospital; University of California, San Diego; University of California, Davis; University of Washington; Oregon Health and Science University
Recruiting - verified June 2011
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days; Procedure: stem cell transplant
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Interventions: Drug: Nifurtimox; Drug: Cyclophosphamide; Drug: Topotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Bayer
Recruiting - verified April 2012
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Irinotecan and ABT-888 in Treating Patients With Metastatic or Unresectable Cancer

Conditions: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride; Drug: veliparib; Genetic: polymorphism analysis; Other: high performance liquid chromatography; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
A Combination of Imatinib Mesylate and Pegylated Interferon α2a in Chronic-Phase Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2a
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified November 2011
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: type of decision aid
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified November 2011
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis
Interventions: Drug: Busulfan; Drug: Cytarabine; Drug: Fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Randomized Trial of Unruptured Brain AVMs

Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Intervention: Drug: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified February 2012
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011